MAPK3 and esophageal squamous cell carcinoma: Moreover, Sp1 and AP-1 activated the transcription of human VIL2 in ESCC cells through binding to the Sp1 site and adjacent AP-1 site of the VIL2 promoter, respectively, involving the MEK/ERK1/2 signaling pathway [22].